Allos Therapeutics recent pullback brings attractive entry point, says Leerink
Leerink views the recent weakness in Allos Therapeutics as an attractive buying opportunity with the Folotyn launch underway. The firm keeps an Outperform rating on the stock. :theflyonthewall.com
News For ALTH From The Last 14 Days
Check below for free stories on ALTH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
